In a report released today, Kyle Rose from Canaccord Genuity maintained a Hold rating on Bioventus (BVS – Research Report), with a price target of $3.00. The company’s shares closed last Thursday at $1.31.
Rose covers the Healthcare sector, focusing on stocks such as Globus Medical, Stryker, and Alphatec Holdings. According to TipRanks, Rose has an average return of 13.6% and a 51.70% success rate on recommended stocks.
In addition to Canaccord Genuity, Bioventus also received a Hold from Craig-Hallum’s Alexander Nowak in a report issued on March 30. However, on April 5, Craig-Hallum assigned a Buy rating to Bioventus (NASDAQ: BVS).
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $13.48 and a one-year low of $0.80. Currently, Bioventus has an average volume of 1.44M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bioventus Inc is a medical technology company incorporated in Delaware on December 22, 2015. The Company is engaged in developing and commercializing orthobiologic products for the treatment of patients suffering from a broad array of musculoskeletal conditions. Its products address the growing need for clinically effective, cost efficient and minimally invasive solutions that enhance the body’s natural healing processes. The Company operates through four segments including Active Healing Therapies-U.S., Active Healing Therapies-International, Surgical and BMP. The Company’s Active Healing Therapies segments offer two types of non-surgical products including non-invasive Exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief.
Read More on BVS:
